TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Median time to repeat dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urea reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean decrease in VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with at least a 50% reduction in VAS scores at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of sinonasal disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p-S6k1 elevation posttraining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p-4E-BP1 levels postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p-ACC elevation postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in protein C activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC membrane fatty acid composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting plasma glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck disability reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of hearing protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intragastric pH >4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Esophageal pH <4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra-abdominal Abscess (IAA)
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of decibels (dB) MD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of ramus height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of open bite
Endpoint domain: Adverse events/effects
Primary endpoint: abstinence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS at the second stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: benefit/risk ratio of extended anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: predictors of recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time to first postoperative passage of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain scores for neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores for right shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores for left shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores for lower back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in striatal DA in response to alcohol ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GO index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in days spent in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: type I muscle fiber satellite cell content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in affected area of SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topical corticosteroid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Topical antibiotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ovulation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum follicular diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Chronic Prostatitis Symptom Index score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of participants achieving blood pressure < 140/90 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of serological influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinical influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Night pain measured on the visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Outcomes Study 36‐Item Short‐Form Health Survey score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean peak HR during MST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average HR increase during MST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average peak SBP during MST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ambulatory activity (steps/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported vigorous-intensity physical activity (metabolic equivalent min/week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of Alizarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acquisition of skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hearing acuity at low frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing acuity at high frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of current smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coronary atheroma progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of MNCH services
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical crown length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial infarction (CK‐MB elevation > x 5 normal level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Repeated revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of gas-bloating syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Amplitude of peristalsis at distal esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum S100-B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborns' birth-weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urinary isoflavone excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic BP (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inhibition of LA-IgG on APC activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of reopenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Allogeneic blood requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: No mineralocorticoid excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median radiographic progression-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in self-selected portion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with serum UA level <6.0 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participation in FOBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Implant clinical survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Workplace sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in PSQI scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in PHQ‐9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of participants achieving normal sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Bone ALP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: leg muscle pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographic lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Perioperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drainage after operation at 24th hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median time of maintaining HbA1c goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients maintaining HbA1c goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-inspiratory air temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimal cross-sectional areas and volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional testing with the single‐legged hop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stress fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Pain at different locations
Endpoint domain: Adverse events/effects
Primary endpoint: Average comfort ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Erythrocyte malondialdehyde output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary isoprostane output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrophage-colony stimulating factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte tissue factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average decrease in GerdQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in HAD anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HIV-1 DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overactive bladder severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUI syndrome severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who remain undelivered 48 hours after preterm premature rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total ischaemic time during ambulatory monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weekly frequency of angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to the start of myocardial ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved general health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade of the surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Breast Cancer (BC) recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor necrosis of 90% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: TIMI grade 3 flow after pPCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial perfusion assessed with MBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular ejection fraction (LVEF) at sixth month of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of developing severe hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neutrophil migratory accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-assessed knowledge in diabetes management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confidence in managing diabetes patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC of BUP‐3G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of BUP‐3G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of norBUP‐3G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of norBUP‐3G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hysterectomy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Attachment Anxiety and Avoidance (ECR‐R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression (CDRS‐R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 11 dhTxB2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 8‐isoPGF2α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sP‐Selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable plasma hyperforin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for i.v. fentanyl for rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of fentanyl doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF concentrations of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of non-aggressive agitated behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cost of health care and social services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preoperative anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma plasminogen activator inhibitor 1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression of joint space loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seroconversion for varicella antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination geometric mean titres (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite CVD events
Endpoint domain: Mortality/survival
Primary endpoint: Responsiveness to analgesics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical anastamotic leak (CAL) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Abstinence from marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to fluoxetine treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pre-existing esophageal eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall mortality at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Overall mortality at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Mental health-related quality of life at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pregnancy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Frequency of achieving 20/40 or better acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of achieving 20/100 or better acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of severe visual loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in target range (70‐180 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average morning blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Locoregional Failure (LRF)
Endpoint domain: Mortality/survival
Primary endpoint: All cause death or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: body mass index at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cord serum IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cord serum IGF-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FR response at L4-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of nasal trauma
Endpoint domain: Adverse events/effects
Primary endpoint: PD20 (methacholine dose producing 20% fall in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neutropenia (grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Diarrhea (grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term adherence to resistance exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: oxidative stress variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in psychosocial well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in obsessional thoughts and compulsions about using alcohol
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of 5-HT 1A receptor binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need for IMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improvement in trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Aphasia quotient score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional communication profile score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraocular pressure (IOP) spikes of 30 mm Hg or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Corneal abrasion in the immediate postoperative period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of insufficient endocervical tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flap size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed ischemic deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severe shunt-dependent hydrocephalus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes